Prosecution Insights
Last updated: April 19, 2026
Application No. 16/762,058

Silk Alcohol Formulations

Non-Final OA §103
Filed
May 06, 2020
Examiner
SABILA, MERCY HELLEN
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan SA
OA Round
7 (Non-Final)
59%
Grant Probability
Moderate
7-8
OA Rounds
2y 8m
To Grant
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
152 granted / 257 resolved
-0.9% vs TC avg
Strong +46% interview lift
Without
With
+45.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
56 currently pending
Career history
313
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
42.0%
+2.0% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 257 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed on and is a U.S. national Stage application under 35 U.S.C. 371 of International Patent Application No. PCT/EP2018/080557 filed 11/08/2018, which claims the benefit of the priority of European Patent Application No. 17201049.8 filed 11/10/2017. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Status Claims 1, 3, 5, 10, 12, 16-23, 26-27, 30-32, 35, 37-43, 47- 56, and 59 are pending. Claims 2, 4, 6-9, 11, 13-15, 24-25, 28-29, 33-34, 36, 44-46, 57-58 are canceled. Claims 1, is amended. Claims 16-23, 26-27, 30-32, 35, 37-43, 47-54, 56, and 59 are withdrawn. Claims 1, 3, 5, 10, 12, and 55 are being examined on the merits in this office action. Claim Rejections - 35 USC § 103 - New In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3, 5, 10, 12, and 55 are rejected under 35 U.S.C. 103 as being unpatentable over Kiyoichi et al. (JPH04300897A – hereinafter “Kiyoichi”) as evidenced by Wigham et al. (Soft Matter, 2025, 21, 2461), in view of Akiho et al. (JP2008169171A – hereinafter “Akiho”), Altman et al. (US20110020409A1 – hereinafter “Altman”), and Liebmann et al. (US20100278882A1 – hereinafter “Liebmann”). Kiyoichi teaches a composition that comprises silk fibroin, alcohol and water, wherein the alcohol is methanol, ethanol, or isopropyl alcohol [0006], wherein the mixing ratio of methanol and water or ethanol and water is from {50:50} to 98: 2 and that silk fibroin is in a concentration up to 20% (Page 1). Examiner notes that as evidenced by Wigham et al., silk fibroin is a silk protein that self assembles (See abstract). Wigham teaches silk fibroin has a molecular weight of about 100 kDa (Page 2468). Kiyoichi teaches that the composition obtained was transparent composition [0008], which reads on clear. Similarly, Akiho teaches an aqueous cosmetic composition comprising from 5% silk fibroin, a lower aliphatic alcohol and water (Abstract; Page 2, ), wherein the alcohol is preferably methyl alcohol, ethyl alcohol, or propyl alcohol, wherein the alcohol / water mixing ratio is preferably greater than 1, but is particularly preferably 5/5 to 10/0 (Page 2, 6th paragraph). Examiner notes that the range of alcohol and water ration encompasses the instant concentration of 60-90% alcohol and 5-39% water. Furthermore, Altman teaches a silk fibroin hydrogel that comprises silk fibroin at a concentration of 1-10% (Abstract; claim 2), and that the composition further comprises 10% water and 90% ethanol [0013, 0029, 0085-0086]. Altman teaches that the formulation exhibits a dynamic viscosity [0124] and further that dynamic viscosity is also known as complex viscosity [0125] and further that the viscosity is about 10 Pas or about 20 Pas or about 30 Pas [0128]. Altman teaches that the hydrogel exhibited optical properties such as transparency [0111-0013, 0203], which reads on clear. Altman further teaches that silk hydrogel formulations for cosmetic use [0155,0176]. Altman further teaches that the silk hydrogel formulation was successful in improving a condition of the skin in an individual in need thereof [0156]. Kiyoichi does not teach that the composition is a fragrance or oil fragrance. Liebmann teaches a cosmetic composition for skin cosmetic, nail cosmetic, hair cosmetic, dermatological, or hygiene, that the composition can be in form of a gel, and that the composition comprises perfume oils [0119-0122]. Liebmann teaches that the composition comprises a silk protein microbead, specifically a C16 silk protein [0019-0021], and that the composition further comprises alcohol such as ethanol and water [0083, 0325]. Liebmann teaches that the composition remained clear [0220, 0270, 0272, 0290, 0292, 0298]. Liebmann teaches that the silk protein has the polypeptide sequence shown in SEQ ID NO: 1 and includes functional equivalents, functional derivatives and salts of this sequence [0021-0022], and the sequence comprises the instant sequence of SEQ ID NO: 1. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Kiyoichi and include fragrance oil or perfume oil in the composition since both reference teach similar composition with silk protein, alcohol and water and for use as a cosmetic composition. One of ordinary skill in the art would be motivated and would have had a reasonable expectation of success in including perfume or fragrance oil in the composition since Liebmann teaches that such compositions that comprises silk protein, alcohol and water can also include fragrance oils and for use as a cosmetic composition. Additionally, one of ordinary skill in the art would have had a reasonable expectation of successfully combining the cited prior art teachings of Kiyoichi, Akiho, Altman and Liebmann , because the cited references hail from the same field of endeavor, i.e. aqueous cosmetic compositions that comprise silk, alcohol and water. The disclosure renders obvious claim 1. Regarding claim 2, Kiyoichi teaches a composition that comprises silk fibroin, alcohol and water, wherein the alcohol is methanol, ethanol, or isopropyl alcohol [0006], wherein the mixing ratio of methanol and water or ethanol and water is from {50:50} to 98: 2 and that silk fibroin is in a concentration up to 20% (Page 1). Examiner notes that the concentrations of Kiyoichi encompass the instant concentrations of claim 2 rendering obvious the claim. Regarding claim 5, Kiyoichi teaches a composition that comprises silk fibroin, alcohol and water, wherein the alcohol is methanol, ethanol, or isopropyl alcohol [0006], wherein the mixing ratio of methanol and water or ethanol and water is from {50:50} to 98: 2 and that silk fibroin is in a concentration up to 20% (Page 1). Examiner notes that as evidenced by Wigham et al., silk fibroin is a silk protein that self assembles (See abstract). Wigham teaches silk fibroin has a molecular weight of about 100 kDa (Page 2468). Further, Akiho teaches molecular weight of about 10,000 to 30,000 (Page 1, 6th paragraph), which reads on 10-30 Kda. Regarding claim 10, Altman teaches that the silk protein may be recombinant [0056]. It would have been obvious to modify Kiyoichi and use a recombinant silk protein as taught by Altman. Regarding claim 12, ]. Liebmann teaches that the silk protein has the polypeptide sequence shown in SEQ ID NO: 1 and includes functional equivalents, functional derivatives and salts of this sequence [0021-0022], and the sequence comprises the instant sequence of SEQ ID NO: 1. It would have been obvious to use the silk protein sequence of Liebmann to prepare the cosmetic composition that comprises silk, alcohol and water since Liebmann teaches that the composition contributed to the moisturization and conditioning of the skin and to an improvement in the feel of the skin [0154]. Regarding claim 55, the Examiner notes that the cited references render obvious a composition comprising the protein, alcohol and water at the recited dosages. Examiner notes that claim 55 is a product-by-process type claim. Product-by-process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. “Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” See MPEP § 2113. Claim 55 is drawn to the aqueous formulation, pharmaceutical and cosmetic formulation of claim 1, and that the formulation is formed by combining the aqueous solutions comprising the structural protein and the aqueous solution comprising the alcohol simultaneously, and wherein the aqueous solutions are mixed for no more than 10 seconds. The formulation is not affected by these limitations, which merely reflect one version of a process that could be used to make the product. The product or formulation could be made in other ways; thus, the limitations do not add patentable weight to the claims. If the product in these claims is the same as or obvious from a product of the prior art, the claim is unpatentable. The formulation comprising silk protein, alcohol, and water and in the recited amounts is clearly disclosed by Kiyoichi, Akiho, Altman and Liebmann. Kiyoichi teaches a composition that comprises silk fibroin, alcohol and water, wherein the alcohol is methanol, ethanol, or isopropyl alcohol [0006], wherein the mixing ratio of methanol and water or ethanol and water is from {50:50} to 98: 2 and that silk fibroin is in a concentration up to 20% (Page 1). Kiyoichi teaches that the composition obtained was transparent composition [0008], which reads on clear. Further, Akiho, Altman and Liebmann teach a similar composition. Thus, claim 55 is rejected as unpatentable over the cited references. Response to Arguments Applicant’s arguments with respect to claim(s) 1, 3, 5, 10, 12, and 55 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mercy H. Sabila whose telephone number is (571)272-2562. The examiner can normally be reached Monday - Friday 5:00 am - 3:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571)270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MERCY H SABILA/Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

May 06, 2020
Application Filed
Aug 03, 2022
Non-Final Rejection — §103
Jan 09, 2023
Response Filed
Mar 06, 2023
Final Rejection — §103
Mar 09, 2023
Response after Non-Final Action
Jun 09, 2023
Request for Continued Examination
Jun 20, 2023
Response after Non-Final Action
Jul 06, 2023
Non-Final Rejection — §103
Dec 12, 2023
Response Filed
Feb 28, 2024
Final Rejection — §103
Aug 05, 2024
Request for Continued Examination
Aug 07, 2024
Response after Non-Final Action
Oct 24, 2024
Non-Final Rejection — §103
Apr 25, 2025
Response Filed
Jun 10, 2025
Final Rejection — §103
Dec 11, 2025
Request for Continued Examination
Dec 12, 2025
Response after Non-Final Action
Feb 16, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595286
FUCOSE-BINDING PROTEIN, METHOD FOR PRODUCING SAME, AND USE OF SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12577282
GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS
2y 5m to grant Granted Mar 17, 2026
Patent 12565516
CARRIER PROTEIN FOR IMPROVING PROPERTIES OF BIOACTIVE PROTEIN
2y 5m to grant Granted Mar 03, 2026
Patent 12534514
BIOLOGICAL AND SYNTHETIC MOLECULES INHIBITING RESPIRATORY SYNCYTIAL VIRUS INFECTION
2y 5m to grant Granted Jan 27, 2026
Patent 12528839
CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+45.7%)
2y 8m
Median Time to Grant
High
PTA Risk
Based on 257 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month